Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC288 in Advanced Solid Tumors
NCT07537881Phase 2Recruiting
- Sponsor
- RemeGen
- Start
- Apr 2026
- Primary completion
- Dec 2029
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Nanobodies (VHH)
- Countries
- 1
01
Overview
A Phase 2 trial of RC288 in solid tumor, sponsored by RemeGen. Started Apr 2026; status: recruiting.
02
Drugs
RC288
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07537881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07537881.